Protai
Tel Aviv, Israel· Est.
AI‑driven proteomics platform accelerating discovery of selective oncology and immunology therapeutics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑driven proteomics platform accelerating discovery of selective oncology and immunology therapeutics.
OncologyImmunology
Technology Platform
AIMS™ integrates structural and functional mass‑spectrometry proteomics with AI‑driven modeling to map disease‑specific protein conformations and design selective modulators.
Opportunities
Rapid expansion of the AIMS™ platform to external partners and successful IND filing for PRT‑001 could unlock significant licensing and co‑development revenue.
Risk Factors
Reliance on unproven AI‑driven target validation and the transition of preclinical assets into clinical candidates pose technical and regulatory uncertainties.
Competitive Landscape
Protai competes with AI‑enabled drug discovery firms and traditional proteomics companies, differentiating itself through integrated structural proteomics and AI for context‑specific target design.